摘要
目的探讨康莱特注射液腹腔灌注治疗恶性腹腔积液的有效性与安全性。方法将诊断为恶性腹腔积液患者42例患者,随机分为康莱特组、顺铂组,观察各组治疗后的近期客观疗效、体力状况评分和不良反应。结果恶性腹腔积液患者单用康莱特治疗组,其有效率低于顺铂组;Karnofsky评分明显高于顺铂组;不良反应发生率明显低于顺铂组。结论康莱特腹腔热灌注治疗恶性腹腔积液无毒性反应,能有效控制恶性腹腔积液,提高生存质量,延长生存期。
Objective To investigate the efficacy and safety of Kanglaite-CHPP in treatment of patients with malignant ascites.Methods Forty-two patients with malignant ascites of advanced cancer were randomized into two groups：22 patients were treated with Kanglaite-CHPP,while the other group of 20 patients were treated with DDP-CHPP.The clinical efficacy,the Karnofsky Performance Status score and side-effects were observed.Results The Kanglaite-CHPP treatment group showed effectiveness rate of 54.5%,which was lower than that of DDP-CHPP group（75.0%）,indicating that there was significant difference between the two groups（P〈0.05）.The Karnofsky Performance Status score was higher in Kanglaite-CHPP group than in DDP-CHPP group.There was significant difference in the side-effects and poisonous effects between the two groups（P〈0.05）.Conclusion Kanglaite-CHPP is an effective therapy for the patients with malignant ascites of advanced cancer.Its side-effects and poisonous effects are slight.It can improve the patients′ quality of life.
出处
《中国肿瘤临床与康复》
2011年第2期187-189,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
